This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsuura, N. Articles by Takada, Y. Search for Related Content PubMed PubMed Citation Articles by Matsuura, N. Articles by Takada, Y.

American Journal of Pathology, Vol 148, 55-61, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells

N Matsuura, W Puzon-McLaughlin, A Irie, Y Morikawa, K Kakudo and Y Takada
Department of Pathology II, Wakayama Medical School, Japan.

Cell adhesion receptors (eg, integrins and CD44) play an important role in invasion and metastasis during tumor progression. The increase in integrin alpha 4 beta 1 expression on primary melanomas has been reported to significantly correlate with the development of metastases. alpha 4 beta 1 is a cell surface heterodimer that mediates cell-cell and cell-extracellular matrix interactions through adhesion to vascular cell adhesion molecule (VCAM)-1 and to the IIICS region of fibronectin. To test the effects of alpha 4 beta 1 expression on tumor cell metastasis, Chinese hamster ovary cells were transfected with human alpha 4 cDNA. Whereas alpha 4-negative Chinese hamster ovary cells developed only pulmonary metastasis, alpha 4-positive Chinese hamster ovary cells developed bone and pulmonary metastasis in 3 to 4 weeks when injected intravenously into nude mice. Bone metastasis was inhibited by antibody against alpha 4 or VCAM-1. Expression of alpha 3 beta 1, alpha 6 beta 1, or alpha V beta 1 did not induce bone metastasis. Expression of alpha 4 beta 1 also induced bone metastasis in K562 human erythroleukemia cells injected into SCID mice. These results demonstrate that alpha 4 beta 1 can induce tumor cell trafficking to bone, probably via interaction with VCAM-1 that is constitutively expressed on bone marrow stromal cells.

This article has been cited by other articles:

				M. B. Meads, L. A. Hazlehurst, and W. S. Dalton The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526. [Abstract] [Full Text] [PDF]

				S. Kumar and S. Ponnazhagan Bone homing of mesenchymal stem cells by ectopic {alpha}4 integrin expression FASEB J, December 1, 2007; 21(14): 3917 - 3927. [Abstract] [Full Text] [PDF]

				C. L. Hall, J. Dai, K. L. van Golen, E. T. Keller, and M. W. Long Type I Collagen Receptor ({alpha}2{beta}1) Signaling Promotes the Growth of Human Prostate Cancer Cells within the Bone. Cancer Res., September 1, 2006; 66(17): 8648 - 8654. [Abstract] [Full Text] [PDF]

				P. Khalili, A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, F. Donate, D. E. Shaw, A. P. Mazar, and S. A. Rabbani A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther., September 1, 2006; 5(9): 2271 - 2280. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				D. L. Olson, L. C. Burkly, D. R. Leone, B. M. Dolinski, and R. R. Lobb Anti-{alpha}4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model Mol. Cancer Ther., January 1, 2005; 4(1): 91 - 99. [Abstract] [Full Text] [PDF]

				Y. Mori, N. Shimizu, M. Dallas, M. Niewolna, B. Story, P. J. Williams, G. R. Mundy, and T. Yoneda Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis Blood, October 1, 2004; 104(7): 2149 - 2154. [Abstract] [Full Text] [PDF]

				B. O. Oyajobi, G. Franchin, P. J. Williams, D. Pulkrabek, A. Gupta, S. Munoz, B. Grubbs, M. Zhao, D. Chen, B. Sherry, et al. Dual effects of macrophage inflammatory protein-1{alpha} on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood, July 1, 2003; 102(1): 311 - 319. [Abstract] [Full Text] [PDF]

				T. Michigami, M. Ihara-Watanabe, M. Yamazaki, and K. Ozono Receptor Activator of Nuclear Factor {{kappa}}B Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma Cancer Res., February 1, 2001; 61(4): 1637 - 1644. [Abstract] [Full Text]

				T. Michigami, N. Shimizu, P. J. Williams, M. Niewolna, S. L. Dallas, G. R. Mundy, and T. Yoneda Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha 4beta 1-integrin enhances production of osteoclast-stimulating activity Blood, September 1, 2000; 96(5): 1953 - 1960. [Abstract] [Full Text] [PDF]

				C. M. Orschell-Traycoff, K. Hiatt, R. N. Dagher, S. Rice, M. C. Yoder, and E. F. Srour Homing and engraftment potential of Sca-1+lin- cells fractionated on the basis of adhesion molecule expression and position in cell cycle Blood, August 15, 2000; 96(4): 1380 - 1387. [Abstract] [Full Text] [PDF]

				R. D. M. Soede, Y. M. Wijnands, M. Kamp, M. A. van der Valk, and E. Roos Gi and Gq/11 proteins are involved in dissemination of myeloid leukemia cells to the liver and spleen, whereas bone marrow colonization involves Gq/11 but not Gi Blood, July 15, 2000; 96(2): 691 - 698. [Abstract] [Full Text] [PDF]

				L. Bogetto, E. Gabriele, R. Cariati, R. Dolcetti, P. Spessotto, C. Doglioni, M. Boiocchi, R. Perris, and A. Colombatti Bidirectional induction of the cognate receptor-ligand alpha 4/VCAM-1 pair defines a novel mechanism of tumor intravasation Blood, April 1, 2000; 95(7): 2397 - 2406. [Abstract] [Full Text] [PDF]

				A. Lochter, M. Navre, Z. Werb, and M. J. Bissell alpha 1 and alpha 2 Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression Mol. Biol. Cell, February 1, 1999; 10(2): 271 - 282. [Abstract] [Full Text]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				T. Tarui, A. P. Mazar, D. B. Cines, and Y. Takada Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction J. Biol. Chem., February 2, 2001; 276(6): 3983 - 3990. [Abstract] [Full Text] [PDF]